Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vabysmo
Pharma
Vabysmo shows signs of recovery as Roche gears up for busy 2027
As the Vabysmo market stabilizes, Roche and investors are turning their attention to several potential blockbuster launches in the next few months.
Angus Liu
Oct 22, 2026 11:20am
After 3 CRLs, FDA approves Outlook's AMD drug Lytenava
Jul 27, 2026 11:51am
Roche defends 6B franc Vabysmo peak target despite another miss
Jul 23, 2026 11:32am
Regeneron sees more regulatory issues, sales declines for Eylea
Apr 29, 2026 12:05pm
Ligand lays out $739M for royalty aggregator compatriot Xoma
Apr 27, 2026 10:19am
UPDATED: Roche Q1 earnings see hits and misses across key products
Apr 24, 2026 1:55pm
